These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Jimenez X; Lu D; Brennan L; Persaud K; Liu M; Miao H; Witte L; Zhu Z Mol Cancer Ther; 2005 Mar; 4(3):427-34. PubMed ID: 15767551 [TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Li J; Huang S; Armstrong EA; Fowler JF; Harari PM Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810 [TBL] [Abstract][Full Text] [Related]
5. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. Shmeeda H; Tzemach D; Mak L; Gabizon A J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844 [TBL] [Abstract][Full Text] [Related]
6. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
7. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061 [TBL] [Abstract][Full Text] [Related]
8. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
9. VEGFR3 does not sustain retinal angiogenesis without VEGFR2. Zarkada G; Heinolainen K; Makinen T; Kubota Y; Alitalo K Proc Natl Acad Sci U S A; 2015 Jan; 112(3):761-6. PubMed ID: 25561555 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950 [TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin. Mei L; Liu Y; Zhang Q; Gao H; Zhang Z; He Q J Control Release; 2014 Dec; 196():324-31. PubMed ID: 25450404 [TBL] [Abstract][Full Text] [Related]
15. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma. Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479 [TBL] [Abstract][Full Text] [Related]
17. Fully human VEGFR2 monoclonal antibody BC001 attenuates tumor angiogenesis and inhibits tumor growth. Xuan ZX; Li LN; Zhang Q; Xu CW; Yang DX; Yuan Y; An YH; Wang SS; Li XW; Yuan SJ Int J Oncol; 2014 Dec; 45(6):2411-20. PubMed ID: 25269419 [TBL] [Abstract][Full Text] [Related]
18. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles. Yamamoto S; Kato A; Sakurai Y; Hada T; Harashima H J Control Release; 2017 Apr; 251():1-10. PubMed ID: 28192155 [TBL] [Abstract][Full Text] [Related]
19. Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. Dicheva BM; ten Hagen TL; Schipper D; Seynhaeve AL; van Rhoon GC; Eggermont AM; Koning GA J Control Release; 2014 Dec; 195():37-48. PubMed ID: 25176578 [TBL] [Abstract][Full Text] [Related]